Agenus Inc. (NASDAQ:AGEN) announced yesterday that the company has entered into a collaboration and license agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer. Agenus Inc. (NASDAQ:AGEN) shares after opening at $2.76 moved to $3.12 on last trade day and at the end of the day closed at $3.06. Company price to sales ratio in past twelve months was calculated as 63.43 and price to cash ratio as 6.95. Agenus Inc. (NASDAQ:AGEN) showed a positive weekly performance of 19.07%.
IGI Laboratories, Inc. (NYSEMKT:IG), a New Jersey -based generic topical pharmaceutical company, on 2 April announced that it has appointed Damian Finio to its Board of Directors. Mr. Finio will serve as the new Chairman of the Company’s Audit Committee. The Company had announced on March 31, 2014 , that Michael Hemric , a Director of the Company has resigned effective April 1, 2014 , and Joyce Erony , the Company’s chairperson and director, had decided not to run for re-election at the Company’s annual meeting on May 27, 2014. IGI Laboratories, Inc. (NYSEMKT:IG) shares advanced 5.30% in last trading session and ended the day on $5.17. IG return on equity ratio is recorded as -27.30% and its return on assets is -11.40%. IGI Laboratories, Inc. (NYSEMKT:IG) yearly performance is 179.46%.
Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (NASDAQ:GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose. Genocea Biosciences Inc. (NASDAQ:GNCA) shares moved up 5.07% in last trading session and was closed at $18.87, while trading in range of $17.95 – $19.15. Genocea Biosciences Inc. (NASDAQ:GNCA) year to date (YTD) performance is 71.55%.
TG Therapeutics, Inc. (NASDAQ:TGTX) consolidated net loss for the year ended December 31, 2013 was $20.5 million, or $0.81 per diluted share, as compared to a consolidated net loss of $26.2 million for the year ended December 31, 2012. TG Therapeutics, Inc. (NASDAQ:TGTX) weekly performance is -6.53%. On last trading day company shares ended up $5.15. TG Therapeutics, Inc. (NASDAQ:TGTX) distance from 50-day simple moving average (SMA50) is -18.76%. Analysts mean target price for the company is $12.75.